Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $10.31, but opened at $10.05. Upstream Bio shares last traded at $10.21, with a volume of 9,719 shares.
Wall Street Analyst Weigh In
Separately, Wall Street Zen raised Upstream Bio from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.50.
View Our Latest Stock Report on UPB
Upstream Bio Stock Performance
The company has a fifty day moving average price of $9.54 and a 200-day moving average price of $10.69.
Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.71 million. Sell-side analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current year.
Institutional Investors Weigh In On Upstream Bio
Several institutional investors have recently made changes to their positions in UPB. BNP Paribas Financial Markets bought a new position in shares of Upstream Bio in the 4th quarter valued at approximately $25,000. US Bancorp DE acquired a new stake in shares of Upstream Bio during the 4th quarter worth approximately $27,000. Legal & General Group Plc acquired a new stake in shares of Upstream Bio during the 4th quarter worth approximately $28,000. New York State Common Retirement Fund acquired a new stake in Upstream Bio in the 1st quarter valued at $29,000. Finally, Summit Investment Advisors Inc. acquired a new stake in Upstream Bio in the 4th quarter valued at $30,000.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
